Archive · 24 May 2025
India's Obesity Treatment Landscape: New Drugs Emerge
New medicines are helping people in India lose weight.
These drugs, like Mounjaro, help people feel less hungry, which helps them eat less.
Obesity, or being very overweight, is a big problem because it can cause other diseases like diabetes.
Many people have tried different ways to lose weight like dieting and exercise, but these drugs are a new option.
The drugs can have side effects, but some people think they are worth it.
Doctors are also prescribing these medicines for people struggling with weight-related issues and recommending diet and exercise for success.
Tirzepatide (Mounjaro) is a new weight-loss drug gaining popularity in India.
The drug is approved for type 2 diabetes and obesity management.
Common side effects include nausea and diarrhea, but people are still using the drug.
The Indian weight-management market is valued at $25.2 billion and is expected to grow.
Obesity is a significant health concern in India, with high prevalence in certain states.
- Who
- Individuals with obesity and type 2 diabetes, doctors, pharmaceutical companies (Eli Lilly), and regulatory bodies (CDSCO).
- What
- The increasing use of new weight-loss drugs like tirzepatide and semaglutide in India to combat obesity and related health issues.
- When
- The drugs were approved for use in 2022 and 2023 and are gaining popularity.
- Where
- India, with specific focus on urban areas and certain states like Kerala and Punjab.
- Why
- Rising obesity rates, increasing awareness of health risks, and the availability of new drug treatments are driving the growth of the weight loss market in India.
Focus on Drug Efficacy
Potential Risks and Benefits
Drug Benefits
Focus on Drug Efficacy
Weight loss drugs may have unwanted side effects.
Potential Risks and Benefits
Drugs aid in weight loss and diabetes control.
Holistic Approach
Focus on Drug Efficacy
Some believe drugs are a quick fix.
Potential Risks and Benefits
Weight loss requires changes in lifestyle, eating habits, etc.
- Drug Name
- Tirzepatide (Mounjaro), Semaglutide (Ozempic)
- Approved Use
- Type 2 diabetes and obesity management
- Cost
- ₹3,500 (2.5 mg vial), ₹4,375 (5 mg vial)
- Common Side Effects
- Nausea, diarrhea, decreased appetite
- Market Value
- $25.2 billion (Indian weight-management market, 2024)
- Expected Market Growth
- 8.79% CAGR between 2025-2033
- Abdominal Obesity Prevalence
- 40% women, 12% men in India (2019-21)